RBC Capital lowered the firm’s price target on Sage Therapeutics (SAGE) to $15 from $26 and keeps a Sector Perform rating on the shares after its Q1 earnings miss. The analyst also cites the company’s limited additional detail on Zurzuvae launch relative to what was already provided by partner Biogen (BIIB), other than some prescription metrics. Sage’s pipeline remains high-risk, though dalzanemdor may still have some shot in Huntington’s Disease despite the recent Parkinson’s Disease failure, the firm tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SAGE:
- Sage Therapeutics reports Q1 EPS ($1.80), consensus ($1.65)
- Biotech Alert: Searches spiking for these stocks today
- SAGE Therapeutics Adjusts Inducement Equity Plan and Sets End Date
- Sage Therapeutics price target lowered to $19 from $34 at Scotiabank
- Sage Therapeutics price target lowered to $17 from $25 at Oppenheimer